M&A Deal Summary

Merck Acquires GlycoFi

On May 9, 2006, Merck acquired life science company GlycoFi from Boston Millennia Partners for 400M USD

Acquisition Highlights
  • This is Merck’s 5th transaction in the Life Science sector.
  • This is Merck’s 22nd largest (disclosed) transaction.
  • This is Merck’s 5th transaction in the United States.
  • This is Merck’s 1st transaction in New Hampshire.

M&A Deal Summary
Date 2006-05-09
Target GlycoFi
Sector Life Science
Buyer(s) Merck
Sellers(s) Boston Millennia Partners
Deal Type Add-on Acquisition
Deal Value 400M USD

Target

GlycoFi

Lebanon, New Hampshire, United States
GlycoFi, Inc., is specialized in a protein-making process called yeast glyco engineering, a process that is considered faster than more conventional methods of making protein-based drugs. GlycoFi was founded in 2000 and is based in Lebanon, New Hampshire.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Merck

Rahway, New Jersey, United States
Category Company
Founded 1891
Sector Life Science
Employees70,000
Revenue 60.1B USD (2023)
DESCRIPTION
Merck office in Palo Alto, California.
Merck office in Palo Alto, California.

Merck is a global healthcare company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company’s operations are comprised of four operating segments. These include Pharmaceutical, Animal Health, Consumer Care and Alliances. Merck's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products. Merck was established in 1891 and is based in Rahway, New Jersey.

DEAL STATS #
Overall 6 of 35
Sector (Life Science) 5 of 32
Type (Add-on Acquisition) 6 of 33
State (New Hampshire) 1 of 1
Country (United States) 5 of 27
Year (2006) 2 of 2
Size (of disclosed) 22 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-05-09 Abmaxis

Santa Clara, California, United States

Abmaxis, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, optimization and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics. Abmaxis has developed and validated a breakthrough antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM), which is used for building an internal product pipeline and for collaborations with global biotech and pharmaceutical partners. The Company's investors include New World Genomics Ltd. and Y's Therapeutics. Abmaxis is located in Santa Clara, California.

Buy $80M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-09-11 NovaCardia

San Diego, California, United States

NovaCardia, Inc. is a pharmaceutical company focuses on the development and commercialization of small molecule drugs for the treatment of cardiovascular diseases.

Buy $366M

Seller(S) 1

SELLER

Boston Millennia Partners

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 1984
PE ASSETS 700M USD
Size Middle-Market
Type Sector Agnostic
DESCRIPTION

Boston Millenia Partners is a growth capital investment firm focused rapidly growing business services and healthcare companies. The Firm generally looks to invest $3 to $10 million in companies at or near profitability with $3 to $30 million in sales. Boston Millenia's geographic preference is for opportunities in the Eastern half of the US. Boston Millenia Partners was formed in 1984 and has a single office in Boston.

DEAL STATS #
Overall 4 of 15
Sector (Life Science) 2 of 4
Type (Add-on Acquisition) 3 of 10
State (New Hampshire) 1 of 1
Country (United States) 4 of 15
Year (2006) 2 of 3
Size (of disclosed) 2 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2006-02-28 WebCT

Lynnfield, Massachusetts, United States

WebCT, Inc. is a provider of e-learning software company serving the education industry. WebCT was founded in 1995 and is based in Lynnfield, Massachusetts.

Sell $178M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2006-06-14 Galt Associates

Seattle, Washington, United States

Galt Associates, Inc. is a provider of safety and risk management solutions for pharmaceutical, medical device and biotechnology companies. Galt Associates was founded in 1994 and is based in Seattle, Washington.

Sell -
Mergr

Product

Company

Legal